Business Wire

Suzano reports Adjusted EBITDA of R$6.3 billion in the second quarter of 2024

Share

Suzano, the world’s largest pulp producer, announces its financial results for the second quarter of 2024 (2Q24).

Adjusted EBITDA totaled R$6.3 billion, a 60% increase on 2Q23, reflecting higher pulp prices, favorable FX rates, increased sales volume, and reduced production costs compared to the same period last year. Operating cash generation totaled R$4.5 billion, the strongest quarterly result since 1Q23, and net revenue came to R$11.5 billion, the strongest quarterly result since 4Q22.

Pulp sales reached 2.5 million tonnes, while paper sales totaled 333,000 tonnes. The cash cost of pulp production, excluding downtime, was R$828 per tonne. Suzano reported a net loss of R$3.8 billion due to the foreign exchange impact in the financial results, with a non-cash impact until maturity of such financial transactions.

Driven by the strong EBITDA performance, Suzano’s US dollar leverage decreased from 3.5 times to 3.2 times, in line with Suzano’s expectation to execute its largest-ever capital investment project within the limits established in the company´s policy. As of the end of June, Suzano had deployed 89% of the R$22.2 billion total planned investment in the Cerrado Project, the world’s largest single-line pulp mill.

Beto Abreu, CEO of Suzano, commented:

“The Cerrado Project’s startup represents a significant milestone in Suzano´s century-long history and its future capacity for value generation. With the lowest structural cost across all our operations, the new mill will enhance our scale and competitiveness in the pulp business. At the same time, we continue to advance in other strategic avenues, including the acquisition of industrial assets from Pactiv Evergreen and taking a significant minority stake in Lenzing.”

Suzano’s new mill began operations on July 21 in the municipality of Ribas do Rio Pardo, Mato Grosso do Sul state, with an annual production capacity of 2.55 million tonnes. The mill´s ramp-up process is expected to be completed in 2Q25.

Between June and July, Suzano also announced the acquisition of a 15% stake in Lenzing, the Austria-based specialist in cellulose fiber production for the textile industry, as well as the acquisition from Pactiv Evergreen of two US-based mills that manufacture liquid packaging board and cupstock.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240808569652/en/

Contacts

Hawthorn Advisors
Jamie Plotnek
suzano@hawthornadvisors.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies20.11.2025 15:00:00 EET | Press release

Cassidy Bio, a biotechnology company developing the first AI-driven genomic foundation model to enhance the design of gene editing therapies, today announced its launch and the closing of an $8 million seed financing round. The company will use the funding to advance its platform, built as a holistic solution designed to bring precision, speed, and clinical confidence to the rapidly growing field of gene therapies. Cassidy Bio’s AI-driven genomic foundation model combines proprietary wet-lab data, population-scale genomic insights, and advanced machine learning to predict the best pairings of guides, enzymes, and delivery modalities, matching them to optimal therapeutic contexts. This creates a scalable capability that supports an end-to-end workflow for genome editing at scale. By moving from siloed trial-and-error to a holistic, predictive approach, Cassidy aims to accelerate the discovery and development of safer, more reliable genetic medicines. “The promise of genome editing will

12 Major Verification Trends in 2026: Regula on the Birth of a New Digital Identity20.11.2025 15:00:00 EET | Press release

How we verify is changing — and so is who and what we verify. Are we dealing with real people, fraudsters, or machines acting on their behalf? A new Regula report on 12 identity verification trendsexamines how these shifts are forcing businesses to rebuild their verification processes to stay ahead of fraud, comply with regulations, and regain eroding customer confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120373343/en/ Identity is leaving the human domain: Regula’s forecast illustrates the emerging need to verify systems, autonomous agents, and machine customers. The new face of fraud The identity threat landscape has entered a new industrial phase, defined by three structural shifts: Machine identity. Identity verification (IDV) is no longer limited to people. It now extends to autonomous systems acting on their behalf — AI agents that can open accounts, submit documents, and bypass checks on their own. Frau

Scientist.com Completes Acquisition by GHO Capital Partners to Accelerate Global R&D Orchestration20.11.2025 14:55:00 EET | Press release

Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform, and GHO Capital Partners LLP (“GHO”), the specialist private equity investor in global healthcare, today announced the successful closing of GHO’s acquisition of Scientist.com. The transaction marks the beginning of an accelerated expansion phase, strengthening Scientist.com’s mission to transform pharmaceutical R&D by streamlining the entire outsourced research lifecycle. “This is a pivotal moment for Scientist.com and for the global research community we support,” said Kevin Lustig, CEO and Chris Petersen, CTO, the founders of Scientist.com. “Partnering with GHO, a team that shares our vision and brings deep expertise in scaling healthcare technology companies, enables us to invest aggressively in our AI-powered orchestration platform and expand our global footprint. Together, we are better positioned than ever to meet growing demand for faster, smarter and more compliant research sourcing.” Fo

SimpliStor™ Solid State Data Recorder Delivers High-Speed, Radiation-Tolerant Storage for Next-Generation Space Missions20.11.2025 14:00:00 EET | Press release

Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions, today announced the release of the SimpliStor™ Solid State Data Recorder (SSDR), a next-generation, radiation-tolerant data recorder that gives satellite operators, system integrators, and spacecraft designers a faster, smarter, and more resilient way to capture and protect mission-critical information in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120514203/en/ Frontgrade's SimpiStor™ 2.5TB Solid-State Data Recorder High-Throughput Performance SimpliStor delivers 2.5 terabytes of storage and 10Gbps throughput in a compact 3U SpaceVPX package, combining exceptional performance with low power consumption. Users can record more data in less time, with latency under 100 microseconds and continuous “store-to-full” recording, ensuring no data loss during peak operations. A 33-minute continuo

Compass Pathways to Participate in Two Investor Conferences in December20.11.2025 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following December investor conferences: 8th Annual Evercore Healthcare Conference – Coral Gables, FL: Fireside chat at 10:00am ET on December 2, 2025 Piper Sandler 37th Annual Healthcare Conference – New York, NY: Fireside chat at 1:30pm ET on December 3, 2025 A live audio webcast of these events will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatment

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye